We are live on ! Find out more
CRL icon

Charles River Laboratories

676 hedge funds and large institutions have $14.1B invested in Charles River Laboratories in 2024 Q1 according to their latest regulatory filings, with 92 funds opening new positions, 257 increasing their positions, 229 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 46

88% more funds holding in top 10

Funds holding in top 10: 815 (+7)

14% more capital invested

Capital invested by funds: $12.4B → $14.1B (+$1.75B)

12% more repeat investments, than reductions

Existing positions increased: 257 | Existing positions reduced: 229

7% more funds holding

Funds holding: 633676 (+43)

0.47% less ownership

Funds ownership: 102.25%101.79% (-0.47%)

47% less call options, than puts

Call options by funds: $52M | Put options by funds: $98.3M

Holders
676
Holders Change
+43
Holders Change %
+6.79%
% of All Funds
9.74%
Holding in Top 10
15
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+87.5%
% of All Funds
0.22%
New
92
Increased
257
Reduced
229
Closed
46
Calls
$52M
Puts
$98.3M
Net Calls
-$46.4M
Net Calls Change
-$20.6M
Name Holding Trade Value Shares
Change
Change in
Stake
EA
401
Everpar Advisors
Oklahoma
$626K -$376K -1,573 -40%
Mercer Global Advisors
402
Mercer Global Advisors
Colorado
$626K +$50.1K +210 +10%
M&T Bank
403
M&T Bank
New York
$600K +$70.2K +294 +15%
WMG
404
WESCAP Management Group
California
$592K -$4.06K -17 -0.8%
SCA
405
Snowden Capital Advisors
New York
$573K -$52.3K -219 -9%
AWM
406
Axxcess Wealth Management
California
$567K +$177K +741 +55%
OAM
407
Ostrum Asset Management
France
$562K
MLICM
408
Metropolitan Life Insurance Company (MetLife)
New York
$561K -$4.54K -19 -0.9%
IB
409
Intrust Bank
Kansas
$552K -$43.2K -181 -8%
LI
410
LMCG Investments
Massachusetts
$549K -$176K -736 -27%
BCV
411
Banque Cantonale Vaudoise
Switzerland
$547K +$30.1K +126 +7%
AFG
412
Atomi Financial Group
New York
$541K +$477K +1,996 New
TMAM
413
Tokio Marine Asset Management
Japan
$538K +$91.5K +383 +24%
MC
414
Moors & Cabot
Massachusetts
$536K -$71.4K -299 -13%
EHWM
415
Eads & Heald Wealth Management
Georgia
$529K -$29.1K -122 -6%
SWP
416
Stratos Wealth Partners
Ohio
$528K -$114K -479 -20%
Aviva
417
Aviva
United Kingdom
$526K +$6.92K +29 +2%
TRCT
418
Tower Research Capital (TRC)
New York
$518K -$1.03M -4,326 -69%
KPWS
419
Kestra Private Wealth Services
Texas
$516K +$2.39K +10 +0.5%
CCM
420
Coldstream Capital Management
Washington
$514K +$31K +130 +7%
HWMA
421
Heritage Wealth Management (Arizona)
Arizona
$506K -$10.3K -43 -2%
WA
422
Wealth Alliance
New York
$503K +$1.43K +6 +0.3%
NG
423
Norden Group
Utah
$497K +$165K +691 +60%
BMCM
424
Bryn Mawr Capital Management
Pennsylvania
$490K
YMRC
425
Yorktown Management & Research Company
Virginia
$488K

CRL Hedge Fund Activity: Q1 2024 in Review

676 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2024, worth a combined $14.1B — up 14% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new CRL positions and 46 closed out — a net gain of 46 holders — while 257 added to existing stakes and 229 trimmed.

The largest buyer was Marshall Wace, opening a new position worth an estimated $158M. The largest seller was Morgan Stanley, cutting an estimated $122M.

  • 676 institutional investors held Charles River Laboratories (CRL) as of Q1 2024, up from 633 in Q4 2023.
  • Funds reported $14.1B of Charles River Laboratories stock for Q1 2024, up 14% quarter-over-quarter.
  • 92 funds opened new Charles River Laboratories positions in Q1 2024 and 46 closed out, a net change of +46 holders.
  • The largest Charles River Laboratories buyer in Q1 2024 was Marshall Wace, an estimated $158M added.
  • The largest Charles River Laboratories seller in Q1 2024 was Morgan Stanley, an estimated $122M sold.

Based on aggregated 13F filings for Q1 2024.